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INTRODUCTION
Substantial changes occur in physiological and biochemical processes during development and growth (Clewell et al., 2002) . Such changes can substantially affect chemical disposition in the growing body resulting in age-related differences in therapeutic efficacy or toxicity (Hines, 2008; Miyagi et al., 2012) . Developmental changes in the expression of xenobiotic metabolizing enzyme systems must be taken into account to better understand age-dependent sensitivity to chemicals as metabolism can be a major determinant of compound disposition and/or toxicity. The increased synthetic pyrethroid deltamethrin neurotoxicity and lethality observed in young rats is a good example of age-related sensitivity due to immature metabolizing enzyme systems overwhelmed by the high chemical doses typically applied in rodent toxicity studies (Sheets et al., 1994; Anand et al., 2006) . Juvenile susceptibility to pyrethroids in animal studies led to the present concern over potential differential sensitivity of pyrethroid insecticides between juveniles and adults due to their predominant exposure to humans in residential settings (Heudorf and Angerer, 2001; Schettgen et al., 2002) .
Hepatic cytochrome P450 (CYPs) and carboxylesterases (CES) are important enzymes involved in pyrethroid metabolism and clearance in both rats and humans (Anand et al., 2006; Godin et al., 2006; Ross et al., 2006; Crow et al., 2007; Godin et al., 2007; Scollon et al., 2009 ).
The CYP enzymes are capable of catalyzing oxidative transformation of the pyrethroids (Scollon et al., 2009 ) and the CES enzymes exhibit hydrolysis of some, but not all pyrethroids in the human . It is noted that significant species differences exist in the relative importance of various CYP and CES enzymes responsible for pyrethroid metabolism and detoxification. In the rat, the oxidative reactions of the pyrethroids are dominated by CYP1A1, 1A2, 2C6, 2C11, and 3A1, whereas CYP2C8, 2C19, and 3A4 are the predominant contributors in the human (Godin et DMD # 74583 al., 2007; Scollon et al., 2009) . In contrast to the rat, human CES1 is important for the hydrolysis of several pyrethroids . In addition, serum esterases demonstrate significant activity in the rat, but not in the human . Moreover, metabolic competency for some pyrethroids develops late in rats as indicated by age-dependent increase in hepatic intrinsic clearance of deltamethrin in rats (Anand et al., 2006; Kim et al., 2010) . However, because of clear species differences in the contribution of each CYP and/or CES enzyme to metabolism of a given pyrethroid, it is difficult to generalize age-dependency in metabolism in humans from rodent data.
Thus, information on the developmental changes of the human CYP and CES enzymes involved in pyrethroid metabolisms are critical to examine the juvenile sensitivity in humans.
The developmental trajectories of human CYP2C8, CYP2C19, CYP3A4, CES1, and CES2, the major metabolic contributors to pyrethroid metabolisms, have been well characterized (Stevens et al., 2003; Koukouritaki et al., 2004; Hines, 2008; Scollon et al., 2009; Hines, 2012; Hines et al., 2016) . However, limited knowledge is available on the ontogeny of human CYP2C8 despite its potential importance in pyrethroid metabolism (Scollon et al., 2009 ) and its abundance in the human liver (Yeo et al., 2004; Achour et al., 2014) . Johnson et al. (2006) demonstrated that the development of CYP2C8 with age was best described by a hyperbolic model, but they had incomplete data on early ages (0-2 years only). Naraharisetti et al. (2010) characterized hepatic CYP2C8 protein expression in individuals with different CYP2C8 genotypes, but their study failed to include early life ages (median age: 46 years, range: 7-70 years). In addition to CYP2C8, human CYP1A2 is expected to demonstrate pyrethroid metabolic activity and the available CYP1A2 data is insufficient for in vitro to in vivo extrapolation (IVIVE) (Scollon et al., 2009 ).
The objective of this study was to determine age-dependent expression levels of human hepatic CYP2C8 and CYP1A2 to fill the current data gap of enzyme ontogeny information, using Koukouritaki et al. (2004) and stored at 80˚C until used for Western blotting analysis. The same samples have been used previously to characterize the developmental expression pattern of other microsomal and cytosolic proteins. Samples from individuals with disease processes that potentially would have involved liver pathology were excluded and more information on clinical exclusion criteria is described in the Supplemental Methods. The demographics of the donors are presented in Table 1 . The median age was 56 days postnatal age with 61% of male and 34% female donors. The collection and described use of these tissue samples was considered exempt by the Children's Hospital and Health System of Wisconsin Institutional Review Board.
Other materials. Primary polyclonal antibody raised in rabbit against human CYP2C8 was obtained from GeneTex (Irvine, CA) (catalogue number GTX113666, lot number 40464). Primary monoclonal antibody raised in mouse against human CYP1A2 was obtained from GeneTex (Irvine, CA) (catalogue number GTX84639, lot number 821403197). Purified secondary antibody against CYP2C8 (catalogue number 926-68021, lot number C40415-04) and purified secondary antibody against CYP1A2 (catalogue number 926-32210, lot number C40528-02) were obtained from LI-COR Biosciences (Lincoln, NE). Specificity of the primary antibodies was verified by DMD # 74583 evaluating cross-reactivity of the CYP2C8 and 1A2 primary antibodies against the same loading   amounts of other cytochrome P450s including CYP1A1, 3A4, 3A5, 1B1, 2B6, 2C9, 2C18, 2C19,   2D6, 2E1, and 2J2 and CYP1A1, 2A6, 3A4, 3A5, 1B1, 2B6, 2C8, 2C9, 2C18, 2C19, 2D6, Immobilon-P-PVDF transfer membrane was purchased from Millipore Corporation (catalogue number IPVH07850; Billerica, MA).
Quantitative Western blot analysis. CYP2C8 and 1A2 expressions in human liver microsomal samples (n=222) were immunochemically measured by Western blot analysis as described previously (Naraharisetti et al., 2010) . Preliminary studies were performed to determine CYP2C8 and 1A2 expression across all ages. Based on the preliminary results, the individual hepatic microsomal samples, either 5 or 10 µg, were separated by SDS-polyacrylamide gel electrophoresis minutes with shaking, and subsequently incubated with a mixture of anti-CYP2C8 (1:500 dilution) or anti-CYP1A2 (1:500 dilution) antibody containing primary antibody diluent at 4C overnight.
Subsequently, each membrane was rinsed with Tris-buffered saline (TBS) containing 0.1% Tween-20, and then incubated with the corresponding secondary antibodies (1:5000 dilution) for 1 hour at room temperature. Blots were scanned using an Odyssey Infrared Imaging Systems (LI-COR Biosciences, Lincoln, NE). In each gel, besides unknown samples and one set of standard samples, a 2 µg of commercial pooled human liver microsome (XenoTech, Kansas City, KS) was added as a quality control sample for interday variation.
The interday coefficients of variation for the microsomal CYP2C8 and CYP1A2 (n=19) were 11.3% and 9.2%, respectively. Non-linear regression analysis was used to construct a calibration curve to quantify the amount of both CYP2C8 and CYP1A2 protein in each individual sample based on the integrated band intensity observed with the respective purified, recombinant proteins. Table S1 ).
Statistical analysis. Scatter plots of CYP2C8-and CYP1A2-specific content as a function of age were used to examine overall trends. Classification and regression tree (CART) analysis (R, Version 3.1.1) was used to evaluate differences in CYP2C8-and CYP1A2-specific content among different age groups. Kruskal-Wallis nonparametric tests were used for statistical comparisons between age groups followed by adjustment for multiple comparisons using Dunn's post hoc test
This article has not been copyedited and formatted. The final version may differ from this version. (GraphPad Prism version 7.01, La Jolla, CA). Other variables were also evaluated using nonparametric testing (GraphPad Prism version 7.01, La Jolla, CA). Linear regression was used to examine relationships between continuous variables (R version 3.1.1) and the strength of the r
RESULTS
Western Blot Analysis of Human Hepatic CYP2C8 and CYP1A2
Western blot analyses revealed a major immunoreactive band at 56kDa corresponding to CYP2C8, whereas for CYP1A2, a single, major immunoreactive band was detected at 58kDa.
Representative Western blots are shown in Figure 1A and 1B. The upper band in parallel with CYP2C8 shown in tested human liver microsomal samples (shown in Figure 1A ) was suspected to be CYP2C9 due to relative cross-reactivity of the CYP2C8 polyclonal antibody with CYP2C9
(Supplemental Figure S1 ). However, this signal did not affect the quantitation of CYP2C8 because CYP2C8 was electrophoretically well separated from the suspected CYP2C9 band under the current experimental conditions. Anti-CYP1A2 antibody was specific to CYP1A2 and did not cross-react with any other recombinant P450 proteins tested in the current study (Supplemental Figure S2) . No cross-reactivity between the anti-CYP2C8 antibody and CYP1A2 protein or between the anti-CYP1A2 antibody and CYP2C8 protein was observed (data not shown).
Ontogeny and Inter-individual Variation in CYP2C8
Human CYP2C8 was detectable in the majority of postnatal samples (142 out of 163 samples). With outliers, defined as having specific contents outside 1.5 times the 25 th to 75 th precentiles, included, the median of microsomal CYP2C8 was 12.62 pmoles/mg microsomal protein (minimum: 0.148 and maximum: 77.98 pmoles/mg microsomal protein); however, only considering the 5 th to 95 th percentile range, the overall distribution of CYP2C8 content for the entire sample varied about 80-fold. The fetal and early infancy developmental expression patterns for CYP2C8 are presented in Figure 2A and B, respectively. With the exception of three outliers, CYP2C8 was either not expressed or expressed at very low levels (<5 pmoles/mg microsomal protein) during the human fetal period (n=60). However, CYP2C8 was readily detected in most Classification tree analysis and confirmatory Kruskal Wallis testing of all prenatal and postnatal samples revealed that microsomal CYP2C8 content was significantly lower among the prenatal samples combined with samples from young infants (<35 days of age) compared to the older age group ( Figure 3A) . This age differential appeared to be driven by the onset of CYP2C8 expression after birth and progressive increase at 35 days of age ( Figure 3A) . CYP2C8 protein levels in the age range of 8 weeks gestation to 35 days postnatal age were less than 1 % of those in the age range of 11-18 years. A second node at 11 years was identified by the initial tree analysis 
Factors Affecting Developmental Expression of CYP2C8 and CYP1A2
Human CYP2C8-specific content was present at significantly higher levels than CYP1A2-specific content among all samples during the gestational period and postnatal development (paired t test, p<0.0001). There was a positive correlation between values of CYP2C8 and CYP1A2 protein content among both the pre-and postnatal age groups (linear regression, r 2 =0.55
and r 2 =0.34, respectively; p<0.0001, each comparison), consistent with the findings from the recent meta-analysis study (Achour et al., 2014 
Correlations between CYP2C Family and CYP3C4 Protein Content
Considering some reported shared regulatory mechanisms between human cytochrome P450 enzymes (Honkakoski and Negishi, 2000) , CYP2C8 protein levels were compared to the previously reported data for CYP2C9, 2C19, and CYP3A4 protein content determined with similar methods using the same tissue samples (Stevens et al., 2003; Koukouritaki et al., 2004) . In contrast to CYP2C8, microsomal CYP2C9 and CYP2C19 are readily detected in fetal and early life hepatic samples (Figure 8) CYP2C8 and CYP1A2 are major hepatic cytochromes P450, comprising about 7% and 4-16% of total microsomal cytochrome P450 content in the adult human liver (Zanger and Schwab, 2013) . Both enzymes play an important role in carrying out oxidative metabolisms of several therapeutic drugs and environmental chemicals including pyrethroids (Godin et al., 2007; Guengerich, 2008; Scollon et al., 2009) . However, there is inadequate knowledge on human CYP2C8 and CYP1A2 ontogeny. Previously reported studies were limited in sample size at early ages (Cresteil et al., 1982; Lee et al., 1991; Johnson et al., 2006; Naraharisetti et al., 2010) . In this study, for the first time, human hepatic CYP2C8 and CYP1A2 was determined using a large number of prenatal and postnatal human liver tissue samples.
Both CYP2C8 and CYP1A2 expression were essentially absent during the gestational period, consistent with increased postnatal expression of both enzymes being linked to birth.
However, the developmental expression patterns after birth were different. Significant CYP2C8 expression was observed in early infant samples with an approximate 8-fold difference in CYP2C8 levels between individuals less than 35 days postnatal age and older donors (>35 days to 18 years).
In contrast, CYP1A2 protein expression exhibited no significant change between the fetal and neonatal periods (~30 days). A progressive increase (~10 fold) in CYP1A2-specific contents was observed after 15 months postnatal age, indicating a delayed CYP1A2 ontogenesis consistent with earlier findings based on more limited data sets (Sonnier and Cresteil, 1998) . Early quantification studies using probe substrates and polyclonal antibodies demonstrated CYP1A2 was either not expressed or was expressed at very low levels in human fetal tissues (Cresteil et al., 1982; Lee et al., 1991) . The study by Sonnier and Cresteil (1998) are consistent with earlier reports.
After the specific age thresholds for significant increases in CYP2C8-and CYP1A2-specific content, microsomal CYP2C8 and CYP1A2 protein expression did not exhibit additional significant age-related differences. This suggests that if any developmental changes in CYP2C8
and CYP1A2 activity occur after about postnatal 35 days and 15 months, respectively, such changes would be modest and may depend on exogenous factors (Hines, 2008; Hines, 2012 with adult samples (median: 46 years, range: 7-70 years), the lack of an observable age effect on CYP2C8 protein expression levels is consistent with our findings. Thus, our results augment the existing, but limited knowledge of human CYP2C8 and 1A2 ontogeny and will enable more accurate assessment of developmental changes in the disposition, efficacy and toxicity of drugs and environmental chemicals.
The variation observed in the overall distribution of CYP2C8 and CYP1A2 content as well as the variation within individual age groups was substantial. Several studies have identified CYP2C8 as highly polymorphic among various ethnic populations, the most common alleles being CYP2C8*2 and CYP2C8*3 (Totah and Rettie, 2005) . CYP2C8*2 is expressed most commonly in African Americans with an allele frequency of 18%, but is very rare in Caucasians and Japanese (Bahadur et al., 2002) . In contrast, CYP2C8*3 is most commonly expressed in Caucasians with an allele frequency of 23% but is quite rare in African Americans and almost absent in Japanese (Soyama et al., 2001; Soyama et al., 2002) . Both CYP2C8*2 and *3 alleles are reported to result in changes in amino acid sequence, leading to altered enzyme expression levels and metabolic activity toward therapeutic drugs (e.g., paclitaxel) and endogenous substrate (e.g., arachidonic acid) in vitro and in vivo (Soyama et al., 2001; Bahadur et al., 2002; Soyama et al., 2002) . In contrast, the clinical relevance of multiple CYP1A2 polymorphisms (e.g., CYP1A2*1 or *6) is controversial (Jiang et al., 2006) . Thus, the presence of CYP2C8 genetic polymorphisms among the liver tissue donors may contribute to the considerable variability observed in CYP2C8-specific content within and between age groups. Diet influences normal cytochrome P450-dependent metabolic maturation processes. For example, using caffeine and dextromethorphan as probes, respectively, formula-fed infants displayed increased CYP1A1 and CYP3A4 metabolic activity compared to breast-fed infants (Le Guennec and Billon, 1987; Blake et al., 2006) . CYP2C8 and CYP1A2 protein expression and metabolic activity also have been shown to be induced by therapeutic drugs and smoking (Totah and Rettie, 2005; Zanger and Schwab, 2013) . These observations implicate genetic polymorphisms and postnatal exposure to dietary and/or other inducing/suppressing agents (e.g., rifampin and carbamazepine) as having a significant role in the developmental regulation of cytochrome P450 expression and functional activity from early infancy (Blake et al., 2006) and likely explains at least some of the interindividual differences in CYP2C8 and 1A2 expression observed in the current study.
Constitutive human CYP1A2 expression only occurs in liver (Zanger and Schwab, 2013) .
CYP1A2 expression also is regulated by the aryl hydrocarbon receptor (AhR) and by other receptors (Pelkonen and Hakkola, 2008) , including the constitutive androstane receptor (AhR) and pregnane X receptor (PXR). Numerous xenobiotics serve as AhR, CAR amd PXR agonistic ligands and thus, can induce CYP1A2 transcription (Blake et al., 2006; Pelkonen and Hakkola, 2008; Zanger and Schwab, 2013) . In contrast, human CYP2C8 is characterized by extrahepatic expression (Klose et al., 1999) as well as its abundance in the liver (Zanger and Schwab, 2013) and is considered the most inducible member of the human CYP2C subfamily (Totah and Rettie, 2005) . Three nuclear receptors, PXR, CAR, and the glucocorticoid receptor, are known to be involved in CYP2C8 induction (Gerbal-Chaloin et al., 2001; Ferguson et al., 2005) . These same nuclear receptors are also involved in the induction and regulation of other CYP2C family genes (CYP2C9 and CYP2C19) and CYP3A4 (Gerbal-Chaloin et al., 2001; Ferguson et al., 2005) . Thus, the correlation of hepatic CYP2C8 with CYP2C9, 2C19, and 3A4 protein levels in the same individuals may be attributed to shared factors that regulate hepatic-specific expression during development (Koukouritaki et al., 2004) .
Establishment of an in vitro and in silico-based evaluation strategy in conjunction with relevant human exposure information is of great importance to risk and safety assessment of potentially vulnerable populations and life-stages. Our data will fill current data gaps in enzyme ontogeny information for IVIVE-supported prediction of age-dependent drug and chemical metabolisms. As an example, IVIVE calculation and in vivo metabolic clearance for a hypothetical compound X, for which CYP1A2 is a major enzyme involved in hepatic metabolism, are described in Supplemental Table S2 and Figure S3 , respectively. The immediate utility of the data from the current study is to predict age-appropriate metabolism parameters for pyrethroid PBPK models.
However, the value of the ontogeny data for these two enzymes is broader, providing the ability to accurately predict age-dependent hepatic clearance for a variety of chemicals, thereby increasing our confidence in risk and safety decisions for early human life stages. CYP2C8 specific content as a function of age was grouped using classification tree analysis to minimize differences within while maximizing differences between age brackets. The resulting data are shown as box and whisker plots in which the horizontal bar represents median CYP2C8 This article has not been copyedited and formatted. The final version may differ from this version. The relationship between microsomal CYP2C8 and CYP3A4 content (linear regression line:
y=0.414 x +2.947, r 2 =0.304, p<0.001). Also, shown is the line of identity, dotted line.
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